STAT Plus: Lawmakers slip a win for pharma into federal spending package
WASHINGTON — Lawmakers quietly tucked a boost for the pharmaceutical industry in the massive, end-of-year…
Category: drug pricing
It’s a bonanza: With drug pricing bill up for a vote, D.C. news outlets are drowning in advocacy ads
WASHINGTON — Pick up this morning’s print edition of Politico and you’ll be hard-pressed to…
Democrats’ drug pricing bill is a sneak peek at the party’s 2020 campaign message
WASHINGTON — If Democrats are spoiling for a 2020 fight focused on anything besides impeaching…
STAT Plus: With new trade deal, Trump deals a blow to drug makers
WASHINGTON — The Trump administration’s Tuesday agreement on a new trade deal with Canada and…
.jpg)
Opinion: H.R. 3 is the wrong path to lower drug costs
Americans want health care to be less expensive. We also want our health care to…
STAT Plus: House Republicans fuel Capitol Hill chaos with competing drug pricing bill
WASHINGTON — Republicans on Monday are set to accelerate Capitol Hill’s drug pricing chaos with…
STAT Plus: Lawmakers ask HHS for greater oversight of patient assistance programs
Amid ongoing concern about the use of patient assistance programs by the pharmaceutical industry, two…
Revamped, bipartisan Senate package takes aim at drug prices — and props up other health programs, too
WASHINGTON — Leaders of a key Senate committee unveiled a new version of a sweeping,…
STAT Plus: More hospital drug spending is going toward cancer immunotherapies
Amid intense scrutiny over prescription drug costs, a new analysis finds some hospitals are spending…
STAT Plus: Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict
Washington has never before been so focused on lowering prescription drug prices. But these biotech…
STAT Plus: More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill
WASHINGTON — Nearly 150 CEOs of emerging biotech companies are sending a unified, stark message…
STAT Plus: A second generic drug maker admits to price fixing as part of a far-reaching probe into generics
A small drug maker called Rising Pharmaceuticals agreed to pay more than $3 million to…
STAT Plus: As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches
As the U.S. grapples with rising costs for prescription medicines, the Trump administration has floated…
Opinion: Protect patient access to drug infusions administered in physician offices
As gastroenterologists, we treat patients in Portland, Ore., and Des Moines, Iowa, with challenging disorders…
STAT Plus: Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before
WASHINGTON — The bipartisan duo behind a 2016 law that poured billions into medical research…
STAT Plus: Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast
Good morning, everyone, an welcome to another working week. We hope the weekend respite, which…
Opinion: Policymakers are taking the wrong approach to health care reform
Here’s what good health care looks like: it emphasizes prevention, is accessible and affordable, and…
STAT Plus: Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work
In a twist on value-based contracting, a drug maker has agreed to offer a larger…
Opinion: In pricing our gene therapy, Bluebird weighed value, shared risk, and a lifetime cap
It is hard to not get emotional when you witness the unfair reality of terrible…
How a billionaire couple greased the skids for Nancy Pelosi’s drug pricing bill
WASHINGTON — When House Democrats pass legislation next month that would slash prescription drug spending…
.jpg)
STAT Plus: Pharma execs tell researchers that multiple sclerosis drug pricing is based on competition, not R&D costs
Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing…
STAT Plus: Generic trade group sues California for an ‘unconstitutional’ law banning pay-to-delay deals
A newly enacted California law that bans so-called pay-to-delay deals between drug makers would reduce…
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
CAMBRIDGE, Mass. — In his first appearance since Bristol-Myers Squibb completed its takeover last week…
STAT Plus: Patient charity settles allegations it helped MS drug makers pay kickbacks
A patient assistance charity has agreed to pay $4 million to settle allegations that it…
STAT Plus: Pharmalittle: Purdue affiliate in China pushes misleading opioid claims; more generics are approved but not yet available
Hello, everyone, and nice to see you again after a brief sojourn in a foreign…
STAT Plus: Biotech venture capitalists form a lobbying coalition to join the drug pricing debate
A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about…
STAT Plus: Pharmalittle: How Purdue planted its ‘anti-story’; how much does that ‘free’ flu shot cost?
Good morning. Elizabeth Cooney here again in Boston while Ed Silverman completes another engagement abroad….